Pericardial Effusion Management
Diagnostic Approach
- The European Society of Cardiology recommends transthoracic echocardiography as the primary diagnostic tool for confirming and evaluating pericardial effusions 1, 2, 4
- Assessment of inflammatory markers is essential to determine if the effusion is associated with systemic inflammation, according to the European Heart Journal 1, 4
- CT or CMR should be considered in cases of suspected loculated effusion, pericardial thickening, masses, or associated chest abnormalities, as suggested by the European Heart Journal 2, 4
Treatment Algorithm Based on Clinical Presentation
- The European Society of Cardiology recommends anti-inflammatory therapy as the first-line treatment when pericardial effusion is associated with pericarditis or systemic inflammation 1, 2, 4
- Aspirin/NSAIDs plus colchicine are recommended as first-line therapy for pericardial effusion with associated inflammation, according to the European Heart Journal 1, 3, 4
- For post-myocardial infarction pericarditis, aspirin is the preferred NSAID, as recommended by the European Society of Cardiology 5
- Corticosteroids may be considered as second-line therapy for patients with contraindications or failure of NSAIDs and colchicine, according to the European Heart Journal 1, 4
Special Etiologies Requiring Specific Management
- Systemic antineoplastic treatment is the baseline therapy for malignant effusions, as recommended by the European Society of Cardiology 6
- Intrapericardial instillation of cytostatic/sclerosing agents may be effective for malignant effusions, according to the European Heart Journal 6
- Antifungal treatment with fluconazole, ketoconazole, itraconazole, or amphotericin B formulations is indicated for fungal pericarditis, as recommended by the European Society of Cardiology 6, 7
Monitoring and Follow-up
- The European Society of Cardiology recommends that the follow-up of pericardial effusion should be based on evaluation of symptoms, echocardiographic assessment of effusion size, and monitoring of inflammatory markers 1, 2, 3, 4
- For small idiopathic effusions, specific monitoring may not be required, according to the European Heart Journal 1, 4
- For moderate to large idiopathic effusions, echocardiographic follow-up every 6 months is reasonable, as recommended by the European Society of Cardiology 1
- Large chronic effusions have a 30-35% risk of progression to cardiac tamponade and may require more vigilant monitoring, according to the European Heart Journal 1, 4